Articles published by OKYO Pharma LTD
OKYO Pharma Announces Chairman Acquires Shares
September 10, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Chairman Acquires Shares
September 05, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
August 27, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma CEO Interview to Air on Bloomberg TV
August 23, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Chairman Acquires Shares
August 23, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Chairman Acquires Shares
August 21, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 15, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
August 06, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
July 10, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
September 15, 2023
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
September 14, 2023
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Limited Announces Withdrawal of Public Offering
September 14, 2023
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Announces Public Offering of Ordinary Shares
September 13, 2023
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023
From OKYO Pharma LTD
Via GlobeNewswire
Tickers
OKYO
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free